Intensive cholesterol-lowering and immune effects in prostate cancer
Official title: Intensive cholesterol-lowering intervention and anti-tumor immunity modeled in prostate cancer
Funded at Cedars-Sinai Medical Center · NIH-11408547 · Data updated 2026-11-12
A study to see if lowering cholesterol with statins can slow prostate cancer and boost the body’s immune response to the cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | September 21, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $692,001 |
| NIH project number | 5R01CA280060-04 |
| Project ID | NIH-11408547 on NIH RePORTER |
Who could benefit from this research
✓Could help
Men with prostate cancer who may benefit from cholesterol-lowering strategies and related immune-boosting approaches.
✕Less likely to help
Patients without prostate cancer or without cholesterol-related pathways affected by the intervention may not experience benefits.
What this research studies
This project will explore how lowering cholesterol may directly slow prostate cancer growth and make the immune system better at fighting it. Researchers will use animal models and parallel human studies to connect cholesterol changes with immune cell activity and tumor characteristics. By examining memory T cells and regulatory signals, the study aims to understand if cholesterol management can enhance anti-tumor immunity in people with prostate cancer. The goal is to identify mechanisms and potential strategies to optimize cholesterol lowering as part of cancer care.
Why it matters
Potential benefit: If successful, this work could lead to improved cancer control through cholesterol management and immune system support.
How similar studies have gone: Preclinical data suggest cholesterol lowering may slow tumor growth and enhance anti-tumor immunity, with early human data showing related immune changes.
Where this research is happening
-
Cedars-Sinai Medical Center
Los Angeles, United States Active
Researchers
- Principal investigator: Kim, Hyung L — Cedars-Sinai Medical Center
- Study coordinator: Kim, Hyung L
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.